ST3
MCID: SPP010
MIFTS: 57

Suppressor of Tumorigenicity 3 (ST3)

Categories: Cancer diseases

Aliases & Classifications for Suppressor of Tumorigenicity 3

MalaCards integrated aliases for Suppressor of Tumorigenicity 3:

Name: Suppressor of Tumorigenicity 3 57 73
Cervical Carcinoma 57 55
Cervical Carcinoma, Tumor-Suppressor Gene Involved in; Ccts 57
Cervical Carcinoma, Tumor-Suppressor Gene Involved in 57
Tumor-Suppressor Gene, Hela Cell Type; Tshl 57
Tumor-Suppressor Gene, Hela Cell Type 57
Cervix Carcinoma 73
Tshl 57
Ccts 57
St3 57

Classifications:



External Ids:

OMIM 57 191181

Summaries for Suppressor of Tumorigenicity 3

MalaCards based summary : Suppressor of Tumorigenicity 3, also known as cervical carcinoma, is related to adenocarcinoma and retinoblastoma. An important gene associated with Suppressor of Tumorigenicity 3 is ST3 (Suppression Of Tumorigenicity 3), and among its related pathways/superpathways are GPCR Pathway and Cell Cycle, Mitotic. The drugs Nolvadex and Ropivacaine have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Description from OMIM: 191181

Related Diseases for Suppressor of Tumorigenicity 3

Diseases related to Suppressor of Tumorigenicity 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.0 TP53 RB1 MYC CDKN2A
2 retinoblastoma 29.9 TP53 RB1 CDKN2A CDKN1A
3 cervix carcinoma 29.8 TP53 FHIT CDKN2A
4 small cell cancer of the lung 29.8 TP53 RB1 MYC CDKN2A
5 cervical adenocarcinoma 29.8 TP53 CDKN2A CDKN1A
6 papilloma 29.7 UBE3A TP53 RB1 PCNA CDKN2A CDKN1A
7 anal squamous cell carcinoma 29.6 CDKN2A TP53
8 malignant mesenchymoma 29.6 TP53 FHIT CDKN1A
9 pancreas adenocarcinoma 29.5 TP53 MYC CDKN2A
10 bladder cancer 29.4 TP53 RB1 MYC CDKN2A CDKN1A
11 glioblastoma 29.2 TP53 RB1 MYC CDKN2A CDKN1A
12 basal cell carcinoma 29.0 TP53 CDKN2A CDKN1A BCL2 BAX
13 nasopharyngeal carcinoma 28.9 TP53 MYC CDKN2A CCNB1 BCL2
14 ovarian cancer 28.8 BAX BCL2 CDKN1A MYC TP53
15 endometrial cancer 28.6 TP53 RB1 MYC CDKN2A CDKN1A BCL2
16 cervical cancer 28.3 UBE3A TP53 RB1 MYC FHIT CDKN2A
17 lung cancer 28.3 TP53 TAP1 RB1 PCNA MYC FHIT
18 breast cancer 28.3 TP53 RB1 PCNA MYC FHIT CDKN1A
19 cataract 40 11.3
20 perrault syndrome 1 11.1
21 cataract, total congenital 11.1
22 cervical adenosquamous carcinoma 11.0
23 high-grade neuroendocrine carcinoma of the cervix uteri 11.0
24 cervical intraepithelial neoplasia 10.3
25 vulvar adenocarcinoma 10.3 TP53 RB1
26 tropical calcific pancreatitis 10.2
27 bladder squamous cell carcinoma 10.2 TP53 CDKN2A
28 keratinizing squamous cell carcinoma 10.2 TP53 CDKN2A
29 spitz nevus 10.2 TP53 CDKN2A
30 actinic cheilitis 10.2 TP53 CDKN1A
31 gallbladder adenoma 10.2 RB1 CDKN2A
32 bladder carcinoma in situ 10.2 TP53 CDKN2A
33 hepatic angiomyolipoma 10.2 RB1 MYC
34 bladder transitional cell papilloma 10.2 TP53 CDKN1A
35 invasive bladder transitional cell carcinoma 10.2 TP53 CDKN1A
36 scrotal carcinoma 10.2 TP53 CDKN2A
37 vulva squamous cell carcinoma 10.2 TP53 CDKN2A
38 atypical follicular adenoma 10.2 TP53 CDKN1A
39 nasal cavity adenocarcinoma 10.2 CDKN2A TP53
40 vulvar disease 10.2 TP53 CDKN2A
41 lip cancer 10.2 TP53 CDKN1A
42 bartholin's gland disease 10.2 CDKN2A TP53
43 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.2 MYC BCL2
44 diffuse large b-cell lymphoma of the central nervous system 10.2 MYC BCL2
45 hypoxia 10.2
46 periosteal chondrosarcoma 10.2 CDKN2A RB1
47 b cell prolymphocytic leukemia 10.2 MYC TP53
48 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A TP53
49 chronic venous leg ulcers 10.2 MYC BCL2
50 barrett's adenocarcinoma 10.2 TP53 FHIT CDKN2A

Graphical network of the top 20 diseases related to Suppressor of Tumorigenicity 3:



Diseases related to Suppressor of Tumorigenicity 3

Symptoms & Phenotypes for Suppressor of Tumorigenicity 3

Clinical features from OMIM:

191181

GenomeRNAi Phenotypes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.63 RB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.63 BCL2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.63 CDKN1A
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.63 CCNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.63 BCL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.63 CCNB1 RB1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.63 BCL2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.63 RB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.63 BCL2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.63 UBE3A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.63 RB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.63 RB1 BCL2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.63 CCNB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-188 10.63 CCNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.63 BCL2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.63 CCNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.63 BCL2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.63 UBE3A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.63 CCNB1 RB1 BCL2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.63 CDKN1A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.63 BCL2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.63 CDKN1A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.63 UBE3A
24 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.63 CCNB1 RB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.63 CCNB1 CDKN1A RB1 UBE3A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.63 RB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.63 UBE3A BCL2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.63 CDKN1A
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.63 BCL2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.63 CDKN1A BCL2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.63 CCNB1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.63 BCL2
33 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 BAX BCL2 CDKN1A CDKN2A PCNA RB1
34 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 BAX BCL2 CDKN1A CDKN2A PCNA RB1
35 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 BAX BCL2 CCNB1 CDKN1A PCNA TP53

MGI Mouse Phenotypes related to Suppressor of Tumorigenicity 3:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.18 BAX BCL2 CDKN1A CDKN2A MYC PCNA
2 hematopoietic system MP:0005397 10.18 BAX BCL2 CDKN1A CDKN2A FHIT MYC
3 growth/size/body region MP:0005378 10.16 BAX BCL2 CDKN1A CDKN2A MYC PCNA
4 immune system MP:0005387 10.16 BAX BCL2 CDKN1A CDKN2A FHIT MYC
5 behavior/neurological MP:0005386 10.15 BAX BCL2 CDKN1A CDKN2A MYC RB1
6 mortality/aging MP:0010768 10.14 BAX BCL2 CDKN1A CDKN2A FHIT MYC
7 integument MP:0010771 10.09 BCL2 CDKN1A CDKN2A FHIT MYC RB1
8 digestive/alimentary MP:0005381 10.08 BCL2 CDKN1A CDKN2A FHIT MYC RB1
9 adipose tissue MP:0005375 10.03 BCL2 CDKN1A MYC PCNA RB1 TP53
10 hearing/vestibular/ear MP:0005377 9.97 BAX BCL2 CDKN1A MYC RB1 TP53
11 neoplasm MP:0002006 9.97 BAX BCL2 CDKN1A CDKN2A FHIT MYC
12 muscle MP:0005369 9.91 BAX BCL2 CDKN1A CDKN2A MYC RB1
13 nervous system MP:0003631 9.91 BAX BCL2 CDKN1A CDKN2A MYC RB1
14 no phenotypic analysis MP:0003012 9.7 CDKN1A CDKN2A MYC PCNA RB1 TP53
15 pigmentation MP:0001186 9.35 BCL2 CDKN2A MYC RB1 TP53
16 reproductive system MP:0005389 9.28 BAX BCL2 CDKN1A CDKN2A MYC PCNA

Drugs & Therapeutics for Suppressor of Tumorigenicity 3

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Nolvadex 18 49 TAMOXIFEN CITRATE AstraZeneca October 1998

Drugs for Suppressor of Tumorigenicity 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
2
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568 5271565
3 Immunologic Factors Phase 4,Phase 3,Phase 2
4 Dermatologic Agents Phase 4,Phase 2
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
6 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
7 Antibodies Phase 4,Phase 2
8 Immunoglobulins Phase 4,Phase 2
9 Vaccines Phase 4
10
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
11
Fluorouracil Approved Phase 3 51-21-8 3385
12
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
14 Protective Agents Phase 3,Phase 2
15 Trace Elements Phase 2, Phase 3,Phase 3
16 Micronutrients Phase 2, Phase 3,Phase 3
17 Anthelmintics Phase 3
18 Antiparasitic Agents Phase 3
19 Adjuvants, Immunologic Phase 3
20 Vitamin B9 Phase 3,Phase 2
21 Anti-Infective Agents Phase 3,Phase 2
22 Vitamins Phase 3
23 Antimetabolites Phase 3,Phase 2
24 Antirheumatic Agents Phase 3,Phase 2
25 Antidotes Phase 3
26 Folate Phase 3,Phase 2
27 Antimetabolites, Antineoplastic Phase 3,Phase 2
28 Calcium, Dietary Phase 3
29 Vitamin B Complex Phase 3,Phase 2
30
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
31
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
32
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
33
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
34
Bupropion Approved Phase 2 34841-39-9, 34911-55-2 444
35
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
36
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
37
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
38
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
39
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
40
Promethazine Approved, Investigational Phase 2 60-87-7 4927
41
Loratadine Approved, Investigational Phase 2 79794-75-5 3957
42
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
43
Acetaminophen Approved Phase 2 103-90-2 1983
44
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
45
Infliximab Approved Phase 2 170277-31-3
46
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
47
Mycophenolic acid Approved Phase 2 24280-93-1 446541
48
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751
49
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
50
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Pre-emptive Sciatic Bloc to Prevent Lower Limb Phantom Pain Completed NCT00528463 Phase 4
2 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
3 Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels Recruiting NCT02637583 Phase 4 PCV13;PPV23
4 Community-based Follow-up of Severely Malnourished Children Completed NCT01157741 Phase 2, Phase 3
5 CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study Completed NCT01948856 Phase 3 J022X ST;Placebo
6 SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed Completed NCT00002551 Phase 3 fluorouracil;leucovorin calcium;levamisole hydrochloride
7 A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes. Unknown status NCT02160132 Phase 2 Methylprednisolone(intravenously in the 1st-2nd-3rd month );Methylprednisolone(intravenously in the 1st-3rd-5th month)
8 Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy Completed NCT01286402 Phase 2 Bupropion SR
9 GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer Completed NCT00068588 Phase 2 capecitabine
10 Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases Completed NCT01578668 Phase 2 erlotinib;pemetrexed;cisplatin;erlotinib
11 Effects of Inhibiting Early Inflammation in Kidney Transplant Patients Recruiting NCT02495077 Phase 2 Methylprednisolone;Mycophenolate Mofetil;Tacrolimus;Acetaminophen;Loratadine;Prednisone;Diphenhydramine
12 Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Active, not recruiting NCT00305682 Phase 2 cyclophosphamide;Fludarabine;mycophenolate mofetil;Sirolimus
13 Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B Not yet recruiting NCT03519360 Phase 2
14 Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A Not yet recruiting NCT03519347 Phase 2
15 Ph I SU011248 + Irinotecan in Treatment of Pts w MG Completed NCT00611728 Phase 1 SU011248 & Irinotecan
16 ECALMIST Versus InSurE in Preterm Infant < 32 Weeks,Multicenter, Multinational RCT Unknown status NCT01848262 Not Applicable
17 Role of Cord Blood Hormones and Epinephrine in the Development of Transient Tachypnea of the Newborn Completed NCT01149928
18 Baby Observational and Nutritional Study Completed NCT01424696
19 Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow Completed NCT01544712 Not Applicable
20 Effects of Carotid Stent Design on Cerebral Embolization Completed NCT00830232 Not Applicable
21 Reproducibility Study of Transcranial Doppler Completed NCT03050567
22 Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors Completed NCT00872677
23 LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study) Recruiting NCT03593395 Not Applicable
24 Systematic Screening for Comorbid Psychological Conditions in Cardiac ACSC Patients With Multimorbidity in the ED Recruiting NCT03188861
25 Blood Markers of Early Pancreas Cancer Recruiting NCT03568630
26 Foot Assessment in People With Diabetes: A Quantitative Diagnostic Approach Recruiting NCT03089463
27 Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies Not yet recruiting NCT03762733

Search NIH Clinical Center for Suppressor of Tumorigenicity 3

Genetic Tests for Suppressor of Tumorigenicity 3

Anatomical Context for Suppressor of Tumorigenicity 3

MalaCards organs/tissues related to Suppressor of Tumorigenicity 3:

41
Cervix, Lymph Node, Endothelial, Testes, B Cells, Bone, Breast

Publications for Suppressor of Tumorigenicity 3

Articles related to Suppressor of Tumorigenicity 3:

(show top 50) (show all 1427)
# Title Authors Year
1
Suicide Gene Therapy of Oral Squamous Cell Carcinoma and Cervical Carcinoma In Vitro. ( 30539538 )
2019
2
Genomic Network-Based Analysis Reveals Pancreatic Adenocarcinoma Up-Regulating Factor-Related Prognostic Markers in Cervical Carcinoma. ( 30406031 )
2018
3
Endometrial cancer after radiation therapy for cervical carcinoma: A radiological approach. ( 30017294 )
2018
4
DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma. ( 29859790 )
2018
5
Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles. ( 30428576 )
2018
6
Dosimetric research into target regions and organs at risk in three-dimensional intracavitary brachytherapy techniques for Chinese patients with cervical carcinoma. ( 30452658 )
2018
7
Toxicity and clinical outcomes with definitive three-dimensional conformal radiotherapy (3DCRT) and concurrent cisplatin chemotherapy in locally advanced cervical carcinoma. ( 30452664 )
2018
8
Effects of forkhead Box protein A1 on cell proliferation regulating and EMT of cervical carcinoma. ( 30468461 )
2018
9
A ruthenium(II) complex containing a p-cresol group induces apoptosis in human cervical carcinoma cells through endoplasmic reticulum stress and reactive oxygen species production. ( 30508750 )
2018
10
Intralesional and subcutaneous application of Viscum album L. (European mistletoe) extract in cervical carcinoma in situ: A CARE compliant case report. ( 30508950 )
2018
11
Association between Epstein-Barr virus (EBV) and cervical carcinoma: A meta-analysis. ( 29021084 )
2018
12
Activation of Wnt-β-catenin pathway in basal-parabasal layers of normal cervical epithelium comparable during development of uterine cervical carcinoma. ( 29079964 )
2018
13
Squamous cell carcinoma antigen, platelet distribution width, and prealbumin collectively as a marker of squamous cell cervical carcinoma. ( 29103023 )
2018
14
The antitumor effect of folic acid conjugated-Auricularia auricular polysaccharide-cisplatin complex on cervical carcinoma cells in nude mice. ( 29132812 )
2018
15
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. ( 29145543 )
2018
16
Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. ( 29182608 )
2018
17
Photo-triggered destabilization of nanoscopic vehicles by dihydroindolizine for enhanced anticancer drug delivery in cervical carcinoma. ( 29195229 )
2018
18
Intravoxel incoherent motion MR imaging of early cervical carcinoma: correlation between imaging parameters and tumor-stroma ratio. ( 29222676 )
2018
19
CDH1 promoter methylation in patients with cervical carcinoma: a systematic meta-analysis with trial sequential analysis. ( 29237293 )
2018
20
RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis. ( 29288321 )
2018
21
Positron emission tomography-magnetic resonance imaging (PET-MRI) for response assessment after radiation therapy of cervical carcinoma: a pilot study. ( 29292485 )
2018
22
The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma. ( 29297234 )
2018
23
Predicting Parametrial Invasion in Cervical Carcinoma (Stages IB1, IB2, and IIA): Diagnostic Accuracy of T2-Weighted Imaging Combined With DWI at 3 T. ( 29323549 )
2018
24
Evaluating the Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scanning in the Staging of Patients With Stage IIIB Cervical Carcinoma and the Impact on Treatment Decisions. ( 29324535 )
2018
25
Quercetin and aconitine synergistically induces the human cervical carcinoma HeLa cell apoptosis via endoplasmic reticulum (ER) stress pathway. ( 29324796 )
2018
26
Prognostic Value of Volume-Based Metabolic Parameters Obtained by 18F-FDG-PET/CT in Patients With Locally Advanced Squamous Cell Cervical Carcinoma. ( 29369948 )
2018
27
Effect of Ku80 on the radiosensitization of cisplatin in the cervical carcinoma cell line HeLa. ( 29375707 )
2018
28
Anticancer activity of crocin against cervical carcinoma (HeLa cells): Bioassessment and toxicity evaluation of crocin in male albino rats. ( 29413694 )
2018
29
The sphingosine kinase 2 inhibitor ABC294640 inhibits cervical carcinoma cell growth. ( 29416779 )
2018
30
Expression of the cervical carcinoma expressed PCNA regulatory (CCEPR) long noncoding RNA is driven by the human papillomavirus E6 protein and modulates cell proliferation independent of PCNA. ( 29427865 )
2018
31
Methylation of the L1 gene and integration of human papillomavirus 16 and 18 in cervical carcinoma and premalignant lesions. ( 29434935 )
2018
32
The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma. ( 29434970 )
2018
33
microRNA-136 inhibits proliferation and promotes apoptosis and radiosensitivity of cervical carcinoma through the NF-κB pathway by targeting E2F1. ( 29452167 )
2018
34
[18F]FDG-PET/CT and MRI for initial pelvic lymph node staging in patients with cervical carcinoma: The potential usefulness of [18F]FDG-PET/MRI. ( 29467905 )
2018
35
RBBP6 promotes human cervical carcinoma malignancy via JNK signaling pathway. ( 29501043 )
2018
36
MicroRNA-409 inhibits the proliferative ability of cervical carcinoma cells by regulating AKT. ( 29509241 )
2018
37
Laparoscopic laterally extended endopelvic resection (LEER) for cervical carcinoma recurring at the pelvic sidewall after concurrent chemoradiotherapy: Our experience in three cases. ( 29510867 )
2018
38
Prognostic Significance of Vascular Endothelial Growth Factor (VEGF) and Her-2 Protein in the Genesis of Cervical Carcinoma. ( 29531585 )
2018
39
MicroRNA-21-5p induces the metastatic phenotype of human cervical carcinoma cells in vitro by targeting the von Hippel-Lindau tumor suppressor. ( 29552160 )
2018
40
Induction of apoptosis in human cervical carcinoma HeLa cells by active compounds from Hypericum ascyron L. ( 29556280 )
2018
41
The in vitro effects of a novel estradiol analog on cell proliferation and morphology in human epithelial cervical carcinoma. ( 29568313 )
2018
42
Effect of Curcumin-Nanoemulsion Associated with Photodynamic Therapy in Cervical Carcinoma Cell Lines. ( 29581972 )
2018
43
Mitofusin-2 Triggers Cervical Carcinoma Cell Hela Apoptosis via Mitochondrial Pathway in Mouse Model. ( 29587277 )
2018
44
Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience. ( 29595759 )
2018
45
TMC120 displayed potent cytotoxic effect on human cervical carcinoma through enhancing the polymerization of microtubules. ( 29596107 )
2018
46
Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma. ( 29603728 )
2018
47
The role of folic acid-conjugated polyglycerol coated iron oxide nanoparticles on radiosensitivity with clinical electron beam (6 MeV) on human cervical carcinoma cell line: In vitro study. ( 29626804 )
2018
48
Up-regulation of miR-20a by HPV16 E6 exerts growth-promoting effects by targeting PDCD6 in cervical carcinoma cells. ( 29710555 )
2018
49
Findings of multiple HPV genotypes in cervical carcinoma are associated with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated with radiotherapy. ( 29721161 )
2018
50
Investigation of tumor-tumor interactions in a double human cervical carcinoma xenograft model in nude mice. ( 29774117 )
2018

Variations for Suppressor of Tumorigenicity 3

Expression for Suppressor of Tumorigenicity 3

Search GEO for disease gene expression data for Suppressor of Tumorigenicity 3.

Pathways for Suppressor of Tumorigenicity 3

Pathways related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 BCL2 CCNB1 CDKN1A CDKN2A MYC RB1
2
Show member pathways
13.43 CCNB1 CDKN1A CDKN2A MYC PCNA RB1
3
Show member pathways
13.05 BAX BCL2 CDKN1A MYC RB1 TP53
4
Show member pathways
13 BAX CCNB1 CDKN1A CDKN2A PCNA TP53
5
Show member pathways
12.99 BAX BCL2 CCNB1 CDKN1A CDKN2A MYC
6
Show member pathways
12.93 BAX BCL2 CDKN1A RB1 TP53
7 12.91 BAX BCL2 CDKN1A CDKN2A MYC RB1
8
Show member pathways
12.89 BAX BCL2 CDKN1A CDKN2A MYC PCNA
9
Show member pathways
12.86 BAX BCL2 CDKN1A CDKN2A MYC TP53
10
Show member pathways
12.84 BAX BCL2 CDKN1A CDKN2A FHIT RB1
11
Show member pathways
12.83 BAX BCL2 CDKN1A CDKN2A MYC RB1
12
Show member pathways
12.72 BAX BCL2 CCNB1 CDKN1A MYC PCNA
13
Show member pathways
12.65 BAX BCL2 RB1 TP53
14
Show member pathways
12.64 BAX BCL2 CDKN1A MYC TP53
15
Show member pathways
12.62 CCNB1 CDKN1A CDKN2A MYC PCNA RB1
16 12.6 CCNB1 CDKN1A CDKN2A PCNA RB1 TP53
17 12.57 BCL2 CDKN1A CDKN2A MYC TP53
18 12.49 BAX CDKN1A CDKN2A MYC PCNA RB1
19
Show member pathways
12.47 BAX CDKN1A MYC PCNA TP53
20
Show member pathways
12.42 CCNB1 CDKN1A CDKN2A RB1 TP53
21 12.39 BAX CDKN1A CDKN2A RB1 TP53 UBE3A
22 12.38 CCNB1 CDKN1A CDKN2A MYC PCNA RB1
23
Show member pathways
12.34 BAX BCL2 CDKN1A RB1 TP53
24
Show member pathways
12.3 BAX BCL2 CDKN1A MYC RB1 TP53
25 12.3 BAX BCL2 CDKN1A MYC RB1 TAP1
26 12.29 BAX CDKN1A MYC TP53
27
Show member pathways
12.29 BAX BCL2 CCNB1 CDKN1A CDKN2A MYC
28
Show member pathways
12.26 CDKN1A CDKN2A MYC RB1
29 12.25 CCNB1 CDKN1A CDKN2A MYC RB1 TP53
30 12.24 BAX BCL2 MYC RB1 TP53
31 12.23 BAX CDKN1A MYC TP53
32 12.22 BAX BCL2 CDKN1A MYC TP53
33 12.14 BCL2 CDKN1A CDKN2A RB1 TP53 UBE3A
34
Show member pathways
12.11 BAX MYC TP53
35
Show member pathways
12.11 BAX CDKN1A TP53
36 12.09 CDKN1A CDKN2A MYC RB1 TP53
37
Show member pathways
12.06 BAX BCL2 CDKN1A MYC
38 12.06 BAX BCL2 CDKN1A CDKN2A MYC TP53
39 12.05 CDKN1A MYC TP53
40 12.05 BCL2 CDKN1A MYC TP53
41
Show member pathways
12.03 CCNB1 MYC PCNA RB1 TP53
42
Show member pathways
12.03 BAX CCNB1 CDKN1A PCNA TP53
43
Show member pathways
12.02 BAX BCL2 TP53
44 12 MYC RB1 TP53
45 12 BCL2 CDKN1A CDKN2A PCNA RB1 TP53
46 11.99 BAX BCL2 TP53
47
Show member pathways
11.97 BAX BCL2 TP53
48 11.89 BAX CCNB1 MYC TP53
49 11.87 CDKN1A RB1 UBE3A
50 11.87 BCL2 CCNB1 CDKN1A MYC

GO Terms for Suppressor of Tumorigenicity 3

Cellular components related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.9 BAX BCL2 CCNB1 CDKN1A CDKN2A FHIT
2 nucleoplasm GO:0005654 9.86 BCL2 CCNB1 CDKN1A CDKN2A MYC PCNA
3 pore complex GO:0046930 8.96 BAX BCL2
4 PCNA-p21 complex GO:0070557 8.62 CDKN1A PCNA

Biological processes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 BCL2 CCNB1 CDKN1A MYC
2 cytokine-mediated signaling pathway GO:0019221 9.96 BCL2 CDKN1A MYC TP53
3 cellular response to DNA damage stimulus GO:0006974 9.95 BAX BCL2 CDKN1A MYC PCNA TP53
4 viral process GO:0016032 9.93 BAX PCNA RB1 TAP1 TP53 UBE3A
5 regulation of cell cycle GO:0051726 9.91 BAX BCL2 CCNB1 RB1
6 negative regulation of cell proliferation GO:0008285 9.91 BAX BCL2 CDKN1A CDKN2A RB1 TP53
7 cellular response to hypoxia GO:0071456 9.86 BCL2 CCNB1 MYC TP53
8 negative regulation of cell growth GO:0030308 9.85 BCL2 CDKN1A CDKN2A TP53
9 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.81 BCL2 CDKN1A RB1
10 positive regulation of fibroblast proliferation GO:0048146 9.81 CCNB1 CDKN1A MYC
11 response to toxic substance GO:0009636 9.81 BAX BCL2 CCNB1 CDKN1A
12 regulation of mitotic cell cycle GO:0007346 9.8 CDKN1A MYC RB1
13 G1/S transition of mitotic cell cycle GO:0000082 9.8 CDKN1A CDKN2A MYC RB1
14 neuron apoptotic process GO:0051402 9.79 BAX BCL2 RB1
15 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.78 BAX BCL2 TP53
16 negative regulation of fibroblast proliferation GO:0048147 9.77 BAX MYC TP53
17 intrinsic apoptotic signaling pathway GO:0097193 9.76 BAX CDKN1A TP53
18 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.71 BAX FHIT TP53
19 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.7 CDKN1A CDKN2A
20 negative regulation of apoptotic signaling pathway GO:2001234 9.7 BAX BCL2
21 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.7 BCL2 TP53
22 apoptotic mitochondrial changes GO:0008637 9.7 BAX BCL2 CDKN2A
23 cellular senescence GO:0090398 9.69 CDKN1A CDKN2A
24 B cell homeostasis GO:0001782 9.69 BAX BCL2
25 release of cytochrome c from mitochondria GO:0001836 9.69 BAX BCL2
26 positive regulation of smooth muscle cell migration GO:0014911 9.68 BCL2 MYC
27 negative regulation of phosphorylation GO:0042326 9.68 CDKN1A CDKN2A
28 positive regulation of protein oligomerization GO:0032461 9.68 BAX TP53
29 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.68 BAX BCL2
30 hypothalamus development GO:0021854 9.67 BAX MYC
31 regulation of mitochondrial membrane permeability GO:0046902 9.67 BCL2 TP53
32 Ras protein signal transduction GO:0007265 9.67 CDKN1A CDKN2A RB1 TP53
33 regulation of protein heterodimerization activity GO:0043497 9.66 BAX BCL2
34 regulation of protein homodimerization activity GO:0043496 9.65 BAX BCL2
35 leukocyte homeostasis GO:0001776 9.65 BAX BCL2
36 cell cycle arrest GO:0007050 9.65 CDKN1A CDKN2A MYC RB1 TP53
37 signal transduction by p53 class mediator GO:0072331 9.64 CDKN1A TP53
38 cellular response to UV GO:0034644 9.62 BAX MYC PCNA TP53
39 positive regulation of developmental pigmentation GO:0048087 9.58 BAX BCL2
40 replicative senescence GO:0090399 9.58 CDKN1A CDKN2A TP53
41 regulation of nitrogen utilization GO:0006808 9.57 BAX BCL2
42 ovarian follicle development GO:0001541 9.46 BAX BCL2 MYC UBE3A
43 response to gamma radiation GO:0010332 9.26 BAX BCL2 MYC TP53
44 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.02 BAX CCNB1 CDKN1A PCNA TP53
45 apoptotic process GO:0006915 10.08 BAX BCL2 CDKN2A FHIT RB1 TP53
46 cell cycle GO:0007049 10.06 CCNB1 CDKN1A CDKN2A RB1 TP53
47 cell proliferation GO:0008283 10.02 BAX BCL2 MYC PCNA TP53

Molecular functions related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 BAX BCL2 FHIT PCNA RB1 TP53
2 protein kinase binding GO:0019901 9.73 CCNB1 CDKN1A CDKN2A TP53
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.37 CDKN1A CDKN2A
4 transcription factor binding GO:0008134 9.35 BCL2 CDKN2A MYC RB1 TP53
5 disordered domain specific binding GO:0097718 9.33 CDKN2A RB1 TP53
6 BH3 domain binding GO:0051434 9.26 BAX BCL2
7 ubiquitin protein ligase binding GO:0031625 9.02 BCL2 CDKN1A FHIT RB1 TP53
8 protein binding GO:0005515 10.18 BAX BCL2 CCNB1 CDKN1A CDKN2A FHIT

Sources for Suppressor of Tumorigenicity 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....